NWRN.SW : Summary for NEWRON PHARMA N - Yahoo Finance

U.S. Markets closed

NEWRON PHARMA N (NWRN.SW)


Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
20.95+0.10 (+0.48%)
At close: 5:30PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close20.85
Open21.20
Bid21.00 x
Ask21.00 x
Day's Range20.75 - 21.25
52 Week Range13.85 - 25.80
Volume21,108
Avg. Volume31,164
Market Cap330.45M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire11 days ago

    Seqirus and Zambon Enter into a Partnership for Parkinson’s Disease Product in Australia and New Zealand

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, is pleased to note the news from its partner Zambon S.p.A., that it has entered into a long-term partnership with Seqirus covering Zambon’s Parkinson’s disease product in Australia and New Zealand.

  • Business Wire18 days ago

    Newron announces encouraging preliminary results of its Phase IIa study with Evenamide in patients with schizophrenia

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, announced today preliminary results of a Phase IIa study with its unique sodium channel blocker, Evenamide , in patients with schizophrenia.

  • Business Wire29 days ago

    Change in Newron’s Senior Management Team

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, announces that Dennis Dionne , Executive Director for Commercial Operations since 2015, has been appointed to the Company’s Senior Management Team as Vice President Commercial Affairs, effective January 1, 2017.